Scholars@Duke
Donald Patrick McDonnell

Donald Patrick McDonnell

Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine
Pharmacology & Cancer Biology
donald.mcdonnell@duke.edu
Box 103057, Durham, NC 27710
2138 MSRB3, 3 Genome Court, Durham, NC 27710

Scholarly Works - Conferences

Abstract 3143: Co-targeting of two distinct androgen receptor-regulated signaling pathways as a therapeutic approach in prostate cancer

Conference Cancer Research · April 3, 2026 AbstractProstate cancer (PCa) is the most frequently diagnosed cancer in men and the second leading cause of cancer-related deaths in the United States. Androgen deprivation therapy (ADT) is initially eff ... Full text Cite

Abstract C130: Identifying a novel therapeutic target, DKK1, in ESR1 mutant breast cancers

Conference Molecular Cancer Therapeutics · October 22, 2025 AbstractEstrogen receptor-positive (ER+) breast cancer accounts for over 75% of all breast cancer diagnoses and remains the most common sub ... Full text Cite

Toward manipulating sex hormones to modulate the adaptive antitumor immune response in liver cancer.

Conference Journal of Clinical Oncology · June 2025 e16246Background: The incidence and mortality of hepatocellular carcinoma (HCC) is three to seven times greater in men than w ... Full text Cite

Thienopyridine Based Estrogen Receptor Modulators Adopt Unique Ligand Binding Poses to Elicit Anti Proliferative Activities in ER + Breast Cancer Cells

Conference Endocrinology · April 21, 2025 Abstract TextOne in eight women will be diagnosed with breast cancer in their lifetimes. Estrogen receptor alpha (ER) drives breast cancer pathology and is expressed in approximately seventy percent of tumor ... Full text Cite

7993 Thienopyrimidine-Based Estrogen Receptor Modulators Adopt Unique Ligand Binding Poses to Elicit Anti-Proliferative Activities in ER+ Breast Cancer Cells

Conference Journal of the Endocrine Society · October 5, 2024 AbstractDisclosure: E.C. Fink: None. S.L. Mateus: None. N. Meganathan: None. V.K. Sammeta: None. J.D. Norris: None. D.P. McDonnell: None. T. Willson: None. S.W. Fanning: None. Full text Cite

The immunomodulatory impacts of endocrine therapy on host immunity in early-stage hormone receptor positive, HER2 negative breast cancer

Conference Journal of Clinical Oncology · January 1, 2024 Background: Endocrine therapy (ET) reduces mortality in hormonally driven breast cancer (BC). The impacts of ET on the estrogen receptor are well known; however, there is limited data on the impact of ET on the host’s immune system. This project aims to el ... Full text Cite

The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.

Conference Journal of Clinical Oncology · June 1, 2023 5060 Background: It has been shown that HOXB13 is an important androgen receptor (AR) coregulator. The primary objective of this analysis was to correlate HOXB13 expression with clinical outcomes in men with mCRPC. Methods: We co ... Full text Cite

Abstract A51: Impact of CaMKK2 inhibition in tumor-associated myeloid cells on CD8+ cytotoxic T-cell recruitment into mammary tumors

Conference Cancer Immunology Research · March 1, 2020 AbstractThe development of cancer immunotherapy has reached an important inflection point, whereby such therapies have been administered with considerable clinical success in many cancers. However, despite s ... Full text Cite

Abstract A44: Pharmacologic targeting of estrogen receptor in melanoma to enhance antitumor immunity

Conference Cancer Immunology Research · March 1, 2020 AbstractMetastatic melanoma is one of the most aggressive, morbid cancers with a median survival of 6-9 months. The development of MAPK-pathway inhibitors and immune checkpoint blockade (ICB) agents (α-PD1 a ... Full text Cite

Combination mTORC1/2 and BCL- XL inhibition in endocrine and CDK4/6-resistant estrogen receptor-positive breast cancer.

Conference Journal of Clinical Oncology · May 20, 2019 e14653 Background: Endocrine therapy plus CDK 4/6 inhibition has led to impressive improvements in progression-free survival in patients with advanced, estrogen receptor positive (ER+)/HER2-negative (HER2-) breast cancer. Resista ... Full text Cite

Abstract 1805: Development of a selective androgen receptor degrader (SARD) for treatment of castration-resistant prostate cancer

Conference Cancer Research · July 1, 2018 AbstractCurrent treatments for prostate cancer are centered on blocking androgen-signaling axis, which is the target of several clinical androgen receptor (AR) antagonists such as enzalutamide. Recent studie ... Full text Cite

Abstract 5496: A predictive model for selective targeting of the Warburg effect through GAPDH inhibition with a natural product

Conference Cancer Research · July 1, 2018 AbstractCancer cells undergo numerous adaptive processes to sustain growth and survival. One notable mechanism is by rewiring metabolism, most prominently through a phenomenon known as the Warburg effect (WE ... Full text Cite

Discovery of a selective androgen receptor degrader (SARD) for treatment of castration-resistant prostate cancer

Conference ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY · August 20, 2017 Link to item Cite

Abstract P3-07-14: Targeting ERR-α regulated lactate metabolism eliminates drug-resistant breast cancer cells

Conference Cancer Research · February 15, 2017 AbstractNovel therapeutic strategies to eliminate chemo-resistant tumour cells responsible for the development of secondary lesions are essential in order to prevent breast cancer relapse. We have developed ... Full text Cite

CYP27A1/27HC/SREBP2 axis is a novel therapeutic target in prostate cancer

Conference European Journal of Cancer · December 2016 Full text Cite

SERMs and SERDs as the cornerstone of endocrine therapy in ER alpha-positive breast cancer

Conference ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY · August 20, 2016 Link to item Cite

Abstract P3-14-04: Effects of the dual selective CYP17 lyase inhibitor and androgen receptor (AR) antagonist, VT-464, on AR+ and ER+ tumor models in vitro and in vivo

Conference Cancer Research · February 15, 2016 AbstractVT-464 is a lyase-selective inhibitor of the dual-activity CYP17A1 enzyme that is required for the synthesis of androgens and estrogens in the gonads, adrenals, and tumors. In addition to its role as ... Full text Cite

Abstract 2703: Overcoming Lapatinib resistance by the fatty acid synthase inhibitor HS-106

Conference Cancer Research · August 1, 2015 AbstractHuman epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase that is overexpressed in about 20% of breast cancers and most often in the more aggressive inflammatory breast cancer (IB ... Full text Cite

Direct effects of the selective CYP17 lyase (L) inhibitor, VT-464, on the androgen receptor (AR) and its oral activity in an F876L tumor mouse xenograft model.

Conference Journal of Clinical Oncology · March 1, 2015 263 Background: MDV3100 inhibits binding of androgens to AR and abiraterone is known to block androgen production through CYP17 inhibition; both are effective treatments for castration-resistant prostate cancer (CRPC, yet cross-r ... Full text Cite

Abstract 3311: The cholesterol/ 27-hydroxycholesterol axis is a novel therapeutic target in castrate resistant prostate cancer

Conference Cancer Research · October 1, 2014 AbstractThe most recent estimates indicate that men have a seventeen percent chance of developing invasive prostate cancer (PCa) over their lifetime. This makes PCa the most commonly diagnosed malignancy amo ... Full text Cite

Abstract 4570: Role of ERRalpha in ovarian cancer

Conference Cancer Research · October 1, 2014 AbstractObjective. The estrogen receptor-related receptor-alpha (ERRα, encoded by ESRRA) has emerged as a key transcriptional regulator of mitochondrial function and has been implicated as a prognostic marke ... Full text Cite

Liver X Receptor signaling pathways and age-related macular degeneration

Conference INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE · April 1, 2014 Link to item Cite

Discovery of novel androgen receptor coactivator binding inhibitors through high-throughput screen

Conference ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY · August 19, 2012 Link to item Cite

Abstract 4542: Dose-dependent effects of progestins on progesterone receptor activity and target gene expression: less is more

Conference Cancer Research · April 15, 2011 AbstractWhile the molecular mechanisms by which the progesterone receptor (PR) regulates breast tumor growth and metastasis have not been fully elucidated, recent studies highlight the fact that PR has a com ... Full text Cite

Fibroid Therapy Enabled by the Hyperbranched Polyglycerol Platform

Conference JOURNAL OF WOMENS HEALTH · October 1, 2009 Link to item Cite

Definition of Functionally Important Mechanistic Differences among Selective Estrogen Receptor Modulators

Conference MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY · November 1, 2008 Link to item Cite

SARMS, SERMS, SGRM

Conference OSTEOPOROSIS INTERNATIONAL · May 1, 2006 Link to item Cite

Development of tissue-selective estrogen receptor modulators

Conference ORGAN-SELECTIVE ACTIONS OF STEROID HORMONES · January 1, 1995 Link to item Cite

Inhibition of the Calcium Calmodulin Kinase Kinase-2/phosphodiesterase-1 signaling pathway as a therapeutic approach in metastatic breast cancer.

Conference Inhibition of the Calcium Calmodulin Kinase Kinase-2/phosphodiesterase-1 signaling pathway as a therapeutic approach in metastatic breast cancer. Full text Cite